Dr. Christopher Piorkowski, Divisional Vice President and Chief Medical Officer of Abbott's Electrophysiology business, is the latest guest on The Top Line podcast.
A seasoned expert in the field of electrophysiology, he joins us to discuss and explain some of Abbott’s latest solutions and advancements, as well as best practices to support treatment for abnormal heart rhythms.

EnSite X, for example, is Abbott’s revolutionary 3D heart mapping software which Piorkowski describes as the company's most important product development of the past decade and compares it to the transition from a gasoline to an electric car in terms of its implications.

And it is easy to see why. EnSite X acts as an ultra-accurate GPS system that helps physicians to locate and understand the areas in a patient’s heart needing ablation. A significant update has been the incorporation of near field technology – this helps physicians to understand which of the electrical signals that they see on the catalyst is truly from the location of a catheter, as opposed to signals that come from further away in so-called far field signals. 

The discussion also takes a turn towards pulsed field ablation, something which Abbott has been working with for well over a decade.

Dr. Christopher Piorkowski, Divisional Vice President and Chief Medical Officer of Abbott's Electrophysiology business, is the latest guest on The Top Line podcast. A seasoned expert in the field of electrophysiology, he joins us to discuss and explain some of Abbott’s latest solutions and advancements, as well as best practices to support treatment for abnormal heart rhythms.
EnSite X, for example, is Abbott’s revolutionary 3D heart mapping software which Piorkowski describes as the company's most important product development of the past decade and compares it to the transition from a gasoline to an electric car in terms of its implications.
And it is easy to see why. EnSite X acts as an ultra-accurate GPS system that helps physicians to locate and understand the areas in a patient’s heart needing ablation. A significant update has been the incorporation of near field technology – this helps physicians to understand which of the electrical signals that they see on the catalyst is truly from the location of a catheter, as opposed to signals that come from further away in so-called far field signals. 
The discussion also takes a turn towards pulsed field ablation, something which Abbott has been working with for well over a decade.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;